REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for blood cancer patients out of options
Disease control Recruiting nowThis is the first human study of an experimental drug called STX-0712 for people with advanced forms of blood cancers (CMML and AML) who have run out of standard treatment options. The main goal is to find a safe dose and see if the drug shows any early signs of fighting the canc…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Solu Therapeutics, Inc • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New chemo combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new chemotherapy combination called CPX-351 in adults with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and under…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for tough blood cancers: stronger treatment before transplant
Disease control Recruiting nowThis study is testing a new, more intensive treatment plan for adults with aggressive blood cancers that are likely to return. The plan involves a combination of chemotherapy drugs and radiation, followed by a stem cell transplant from a donor. The goal is to see if this stronger…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough blood cancers: testing a Two-Pronged transplant attack
Disease control Recruiting nowThis study is testing a new approach to stem cell transplant for adults with aggressive blood cancers that have returned or not responded to treatment. The goal is to find the safest dose of radiation when combined with strong chemotherapy before the transplant, aiming to better …
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New antibody injection tested to control rare blood cancers
Disease control Recruiting nowThis study is testing whether a medication called canakinumab, given as a monthly injection, can help control certain low-risk blood and bone marrow disorders. It aims to see if the treatment improves blood counts, reduces the need for blood transfusions, and is safe for patients…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called onvansertib for people with rare, aggressive blood cancers that have come back or stopped responding to available treatments. The main goals are to find a safe dose and see if the drug can help control the disease. The stud…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new combination of two drugs, axatilimab and azacitidine, for people with advanced or hard-to-treat blood cancers. The first part of the study aims to find the safest and most effective dose. The second part will see how well the drug combination works to …
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Triple-Threat attack on tough blood cancers shows promise
Disease control Recruiting nowThis study is testing a new combination of three drugs—azacitidine, venetoclax, and gilteritinib—for adults with certain aggressive blood cancers that have returned or not responded to treatment. The main goals are to find the safest dose and see if adding gilteritinib helps pati…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC